Patents by Inventor Dubravka Markovic
Dubravka Markovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8162969Abstract: An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.Type: GrantFiled: October 15, 2009Date of Patent: April 24, 2012Assignee: Obalon Therapeutics, Inc.Inventors: Mark C. Brister, Nelson Quintana, Kaushik A Patel, Neil R. Drake, Antonio C. Llevares, Dubravka Markovic, Andrew P. Rasdal, Amy D. L. VandenBerg
-
Publication number: 20110270158Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Applicant: DexCom, Inc.Inventors: James H. Brauker, Mark A. Tapsak, Sean T. Saint, Apurv U. Kamath, Paul V. Neale, Peter C. Simpson, Michael Robert Mensinger, Dubravka Markovic
-
Patent number: 7976492Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.Type: GrantFiled: August 6, 2009Date of Patent: July 12, 2011Assignee: DexCom, Inc.Inventors: James H. Brauker, Mark A. Tapsak, Sean T. Saint, Apurv U. Kamath, Paul V. Neale, Peter C. Simpson, Michael Robert Mensinger, Dubravka Markovic
-
Patent number: 7875293Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.Type: GrantFiled: May 10, 2004Date of Patent: January 25, 2011Assignee: DexCom, Inc.Inventors: Mark Shults, James H. Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic
-
Patent number: 7860545Abstract: An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.Type: GrantFiled: February 26, 2008Date of Patent: December 28, 2010Assignee: DexCom, Inc.Inventors: Mark C. Shults, James H. Brauker, Victoria Carr-Brendel, Mark A. Tapsak, Dubravka Markovic, Stuart J. Updike, Rathbun K. Rhodes
-
Patent number: 7854745Abstract: An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.Type: GrantFiled: February 19, 2010Date of Patent: December 21, 2010Assignee: Obalon Therapeutics, Inc.Inventors: Mark C. Brister, Nelson Quintana, Kaushik A. Patel, Neil R. Drake, Antonio C. Llevares, Dubravka Markovic, Andrew P. Rasdal, Amy D. L. VandenBerg
-
Publication number: 20100137897Abstract: An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.Type: ApplicationFiled: February 19, 2010Publication date: June 3, 2010Applicant: Obalon Therapeutics, Inc.Inventors: Mark C. Brister, Nelson Quintana, Kaushik A. Patel, Neil R. Drake, Antonio C. Llevares, Dubravka Markovic, Andrew P. Rasdal, Amy D.L. VandenBerg
-
Publication number: 20100100117Abstract: An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.Type: ApplicationFiled: October 15, 2009Publication date: April 22, 2010Applicant: Obalon Therapeutics, Inc.Inventors: Mark C. Brister, Nelson Quintana, Kaushik A. Patel, Neil R. Drake, Antonio C. Llevares, Dubravka Markovic, Andrew P. Rasdal, Amy D.L. VandenBerg
-
Publication number: 20100100116Abstract: Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo.Type: ApplicationFiled: October 15, 2009Publication date: April 22, 2010Applicant: Obalon Therapeutics, Inc.Inventors: Mark C. Brister, Kaushik A. Patel, Andrew P. Rasdal, Nelson Quintana, Neil R. Drake, Antonio C. Llevares, Dubravka Markovic, Amy D.L. VandenBerg
-
Publication number: 20090299276Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.Type: ApplicationFiled: August 6, 2009Publication date: December 3, 2009Applicant: DexCom, Inc.Inventors: James H. Brauker, Mark A. Tapsak, Sean T. Saint, Apurv U. Kamath, Paul V. Neale, Peter C. Simpson, Michael Robert Mensinger, Dubravka Markovic
-
Patent number: 7591801Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.Type: GrantFiled: February 26, 2004Date of Patent: September 22, 2009Assignee: Dexcom, Inc.Inventors: James H. Brauker, Mark A. Tapsak, Sean T. Saint, Apurv U. Kamath, Paul V. Neale, Peter C. Simpson, Michael Robert Mensinger, Dubravka Markovic
-
Publication number: 20080228051Abstract: An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.Type: ApplicationFiled: February 26, 2008Publication date: September 18, 2008Applicant: DexCom. Inc.Inventors: Mark C. Shults, James H. Brauker, Victoria Carr-Brendel, Mark A. Tapsak, Dubravka Markovic, Stuart J. Updike, Rathbun K. Rhodes
-
Publication number: 20080228054Abstract: An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.Type: ApplicationFiled: February 26, 2008Publication date: September 18, 2008Applicant: DexCom, Inc.Inventors: Mark C. Shults, James H. Brauker, Victoria Carr-Brendel, Mark A. Tapsak, Dubravka Markovic, Stuart J. Updike, Rathbun K. Rhodes
-
Publication number: 20070235331Abstract: Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.Type: ApplicationFiled: May 18, 2007Publication date: October 11, 2007Applicant: DexCom, Inc.Inventors: Peter Simpson, Robert Boock, James Petisce, Mark Brister, Monica Rixman, Kum Ming Woo, Lisa Nguyen, Seth Brunner, Arthur Chee, Melissa Nicholas, Matthew Wightlin, Jack Pryor, Dubravka Markovic
-
Publication number: 20060204536Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.Type: ApplicationFiled: May 3, 2006Publication date: September 14, 2006Inventors: Mark Shults, James Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic
-
Publication number: 20060198864Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.Type: ApplicationFiled: May 3, 2006Publication date: September 7, 2006Inventors: Mark Shults, James Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic
-
Publication number: 20050192557Abstract: Abstract of the Disclosure Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.Type: ApplicationFiled: February 26, 2004Publication date: September 1, 2005Applicant: DexComInventors: James Brauker, Mark Tapsak, Sean Saint, Apurv Kamath, Paul Neale, Peter Simpson, Michael Mensinger, Dubravka Markovic
-
Publication number: 20050033132Abstract: An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.Type: ApplicationFiled: May 14, 2004Publication date: February 10, 2005Inventors: Mark Shults, James Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic, Stuart Updike, Rathbun Rhodes
-
Publication number: 20050031689Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.Type: ApplicationFiled: May 10, 2004Publication date: February 10, 2005Applicant: DexCom, Inc.Inventors: Mark Shults, James Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic